

## Expansion of Evonik's MetAMINO® production in Singapore is completed

- MetAMINO® production in Singapore back operating at full capacity
- Collaboration with Linde enables the use of green hydrogen
- Product carbon footprint of Evonik's DL-methionine from Singapore further reduced by six percent

**Essen, Germany.** The expansion of Evonik's MetAMINO® (DL-methionine) production facilities in Singapore has been completed. The MetAMINO® production on Jurong Island is again running at full capacity, after shutdowns in Q4/2023 and Q2/2024. The production capacity has been increased by 40,000 metric tons, bringing the total to 340,000 metric tons per year. The expansion was accomplished ahead of schedule.

Through process intensification, Evonik has optimized its methionine production plants, generating a surplus of steam that is used to produce on-site electricity.

Linde, one of Evonik's partners on Jurong Island, has designed, constructed, and is operating a nine-megawatt alkaline electrolyzer plant, which is the largest of its kind ever installed in Singapore. The unit enables Evonik's efforts to use green hydrogen required for the MetAMINO® production and reflects the company's commitment to sustainability and reducing its environmental impact.

"Our collaboration with Linde on the implementation of green hydrogen in our Singapore facilities is a testament to our commitment to sustainability. We work closely with our partners to build a more sustainable future," says Dr. Harald Schwager, Deputy Chairman of the Executive Board.

Evonik's DL-methionine plants in Singapore have reduced the product carbon footprint of MetAMINO® at this site (Scope 1+2+3) by six percent compared to before the expansion.

28 August 2024

**Main press contact**

**Yama Olumi**  
Head of Market Communications  
Animal Nutrition  
Phone + 49 6181 59-12437  
yama.olumi@evonik.com

**Alternative press contact**

**Dr. Jürgen Krauter**  
Head of Market Communications  
Evonik  
Phone +49 6181 59-6847  
juergen.krauter@evonik.com

**Evonik Industries AG**  
Rellinghauser Straße 1-11  
45128 Essen  
Germany  
Phone +49 201 177-01  
www.evonik.com

Supervisory Board  
Bernd Tönjes, Chairman  
Executive Board  
Christian Kullmann, Chairman  
Dr. Harald Schwager, Deputy Chairman  
Maike Schuh, Thomas Wessel

Registered Office is Essen  
Register Court Essen Local Court  
Commercial Registry B 19474

The expansion of the MetAMINO® production facilities was inaugurated during a festive ceremony attended by Ms. Grace Fu, Singapore’s Minister for Sustainability and the Environment and Minister-in-Charge of Trade Relations: “Evonik’s latest expansion will help address two urgent problems – climate change and food production – in a sustainable way. By increasing its product yield with fewer emissions, Evonik’s facility will help to feed a growing population while streamlining our carbon footprint. Congratulations to Evonik for paving the way to a more sustainable future,” said Minister Fu.

In 2023, Evonik set its own science-based targets that have been approved by the Science Based Targets Initiative (SBTi) as consistent with a well-below 2°C (WB2C) pathway. “We are committed to reducing emissions in line with the latest climate science, and consequently, we have a long-term ambition to expand our targets to align with a 1.5°C warming pathway, and reach net-zero emissions by 2050”, says Gaetano Blanda, head of the Animal Nutrition business line.

MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein. Animal Nutrition is part of Evonik’s Nutrition & Care division and contributes significantly to the profitable growth of Nutrition & Care through its self-financing power.

#### **Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

#### **About Nutrition & Care**

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

### **Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.